Mammary epithelial regeneration implies the existence of cellular progenitors with retained replicative capacity, prolonged lifespan and developmental potency. Evidence exists that DN-p63 isoforms preserve these features by modulating p53 activity in basal epithelia. DN-p63 mRNA levels decline at the onset of differentiation suggesting that its transcriptional regulation may contribute to the initiation of differentiation. To study transcriptional regulation of DN-p63, a 10.3 kbp fragment containing the DN-p63 promoter was isolated. We report here that DN-p63 is a positive and negative transcriptional target of p53 and DN-p63-a, respectively. Disruption of p53 activity or expression abolishes the expression of DN-p63-a. This regulation is mediated by a p53-binding element sufficient to confer these activities to a heterologous promoter. Chromatin immune-precipitation indicates that, in asynchronously growing cells, p53 occupies this element. In response to DNA damage, DN-p63-a is recruited to this element as transcription of DN-p63 declines. Disruption of DN-p63-a expression had differential effects on the transcriptional regulation of several p53-target genes. These findings indicate that p53 contributes to the preservation of basal epithelia by driving the expression of DN-p63 isoforms. These studies also suggest that in response to genotoxic stress, DN-p63-a mediates the silencing of its own promoter thereby altering the pattern of p53-target gene expression.
Introduction
A common feature of epithelial structures is the ability to undergo multiple rounds of cellular regeneration. In the mammary gland, each regenerative cycle occurs as a biphasic sequence of proliferation and apoptosis (Hovey et al., 2002) in which a small portion of the previous lobular structure persists (Masso-Welch et al., 2000) .
This remnant is believed to be the site of reinitiation of cellular proliferation (Hennighausen and Robinson, 1998) . Subsequent regenerative cycles depend upon a subset of epithelial precursors that resist terminal differentiation and retain proliferative capacity (Li et al., 1998; Smith and Chepko, 2001 ). The identification of this subset represents an important step in the overall goal of understanding the events that regulate cellular differentiation of mammary epithelia and the consequences of their subversion.
In mammary gland, the risk of carcinogenesis correlates with the number of proliferative cycles. Each cycle represents an opportunity for mutations to occur that may undermine control of differentiation and contribute to carcinogenesis. While the protective effects of apoptosis neutralize many mutations, others may be propagated within a subset of epithelial cells that resist developmental apoptosis. Genetic studies in mice have established an important role for the tumor suppressor p53 in the regulation of apoptosis during involution (Jerry et al., 1999) . P53 null mice exhibit delayed apoptosis during involution (Jerry et al., 2002) , suggesting that the ability to resist developmental apoptosis depends upon factors that oppose p53 activity. Other studies demonstrate that isoforms of the p53-family member, p63 oppose p53 activity (Yang et al., 1998; Kaelin, 1999; Yang and McKeon, 2000) . Six isoforms of p63 are divided into two groups based on differential promoter selection (Yang et al., 1998; Kaelin, 1999) . The trans-activating (TA) group displays an aminoterminus that is homologous to the trans-activation domain of p53 and is capable of complementing certain activities of p53 (Yang et al., 1998; Marin and Kaelin, 2000; Dohn et al., 2001) . The DN group lacks the aminoterminus and opposes many of the activities of p53 (Yang et al., 1998; van Bokhoven and Brunner, 2002) . A second important difference between p53 and p63 is the observed pattern of expression (Yang et al., 1998; Parsa et al., 1999; Hall et al., 2000; Signoretti et al., 2000; Nylander et al., 2002) . P53 is widely expressed at low levels and positively regulated by protein stabilization in response to apoptotic signals such as genotoxic stress. P63 is expressed in a tightly regulated basal epitheliaspecific pattern. Isoform-specific immunohistochemistry indicates that DN-isoforms predominate in the basal layers of several epithelial structures (Nylander et al., 2002) . This result, coupled to the ability of DN-p63 isoforms to oppose the activities of p53, suggests that these isoforms preserve basal epithelia by modulating p53 activity.
Genetic studies demonstrate that p63 gene products act to preserve regenerative capacity of epithelial structures (Mills et al., 1999; Yang et al., 1999) . Mice lacking p63 display severe defects in limb, cranio-facial and epithelial development. Additionally, the skin was hypoplastic and was shown to have undergone a program of nonregenerative differentiation . Several human genetic disorders have been linked to mutations within the coding region of the p63 gene (van Bokhoven and McKeon, 2002) . Consistent with the murine phenotype, these disorders are characterized by regenerative failure of epithelial structures. These studies indicate that p63 functions to maintain the regenerative capacity of epithelial structures throughout the body. They also support a model in which disruption of p63 expression or activity represents an early step in cellular differentiation. In a developmental model of corneal keratinocytes, DN-p63 isoforms maintain multipotency and loss of DN-p63-a mRNA correlates with transient amplification of limbal epithelia (Pellegrini et al., 2001) . In multilayered epithelial structures such as skin, p63 protein levels diminish along a basal-apical gradient (Yang et al., 1998; Parsa et al., 1999) . In luminal epithelial structures such as the mammary gland or prostate, the number of cell layers is reduced, making the decline of p63 more pronounced (Signoretti et al., 2000; DiRenzo et al., 2002) . In situ hybridization of skin sections indicated loss of p63 mRNA during differentiation. Importantly, the gradient of mRNA loss was more pronounced than that of protein, indicating that p63 levels decline through transcriptional repression (Parsa et al., 1999) . These studies support a model, which holds that transcriptional repression of p63 is an early event in the initiation of epithelial cell differentiation.
While epithelial progenitors must resist developmental apoptosis, it follows that under conditions of genotoxic stress, this resistance would be subverted to allow for the destruction of damaged cells. Studies using mouse embryo fibroblasts, lacking either p63 or p73 or bearing a p63/p73 double knockout, indicate that in response to genotoxic stress both p63 and p73 make significant contributions to the apoptotic response in a p53 wild-type background (Flores et al., 2002) . That p63 functions to resist developmental apoptosis and promote genotoxic apoptosis raises questions regarding mechanisms by which this duality is achieved. Studies indicate that p73 is a target of DNA-damage-dependent acetylation, which potentiates the pro-apoptotic functions of p73 (Costanzo et al., 2002) . It will be important to determine if this mechanism applies to p63 and is specifically a response to genotoxic stress.
Previously, we reported the establishment of an immortalized mammary epithelial cell (IMEC) line by overexpression of hTERT in primary mammary epithelia. IMECs display a basal epithelial phenotype based upon cytokeratin profile and expression of DN-p63-a (DiRenzo et al., 2002) . IMECs exclusively express the DN-p63-a isoform, consistent with reports that DNisoforms predominate in basal epithelia of the mammary gland (Nylander et al., 2002) . To study the transcriptional regulation of DN-p63 isoforms in IMECs, we isolated a 10.3 kb fragment of the DN-specific p63 promoter and identified a well-conserved p53-binding element. During asynchronous growth, p53 directs expression of DN-p63-a through this element, and disruption of p53 activity or expression abolishes DNp63-a expression. In response to genotoxic stress, DNp63-a is recruited to this element and may contribute to the downregulation of DN-p63 promoter activity. We present data that loss of DN-p63-a has differential effects on p53-target gene expression. These studies identify DN-p63 as a transcriptional target of p53 and suggest a bidirectional role for the p53-binding element that has differential consequences for expression of p53-target genes.
Results

Identification of a p53-binding element within the DN-p63 promoter
To better understand the signals that govern maintenance of multipotency, we sought to identify factors that influence the expression of DN-p63-a by characterizing the DN-p63 promoter. Three short fragments of genomic DNA immediately upstream of exon 3 0 were amplified and cloned into a modified version of pGL3. Transient transfection of these plasmids revealed high levels of promoter activity in IMECs and MCF-7 (Figure 1a) which, coupled to their genomic location, suggested that they represented the DN-p63 promoter. The similarity between IMEC and MCF-7, which fail to express p63, indicate that these fragments lacked sufficient information to confer cell-type-specific expression. To identify a larger genomic fragment, Southern blotting was performed using IMEC genomic DNA and a 10.3 kbp HindIII fragment was identified (Figure 1b ). This fragment was subsequently identified in the BAC RP11-37316 and subcloned into pAlter-1 and pGL3-basic for further analysis. Visual and computer-assisted inspection of DN-p63 promoter sequences identified a well-conserved p53-binding element at position À629 to À607 relative to the start of transcription (Figure 1c) , suggesting that p53 family members may regulate DNp63 promoter activity through this element. To test this, DNA affinity chromatography of IMEC nuclear extracts was carried out to enrich for factors capable of binding the identified p53-binding element, and the retained fractions were subjected to Western blot analysis. In these studies, both wild-type p53 and DNp63-a were capable of binding to the wild-type sequence located within the DN-specific p63 promoter (Figure 1d ). Importantly, neither p53 nor DN-p63-a was detected bound to the mutated sequence shown in Figure 1c . These studies demonstrate that p53 and DN-p63-a are capable of binding the p53-binding element.
The DNA-binding studies suggested that the p53-binding element might mediate a transcriptional response to either p53 or DN-p63-a. To test this, five copies of the element were cloned upstream of the minimal thymidine kinase promoter from HSV fused to luciferase. This reporter, (p53RE) 5 -tk-luc, or the parental, tk-luc, was cotransfected with expression plasmids encoding wild-type p53, DN-p63-a or both into IMECs, which express both p53, and DN-p63-a and SAOS2, which fail to express either (DiRenzo et al., 2002) . Under these conditions, p53 induced a 159.8-fold activation of (p53RE) 5 -tk-luc compared to a 1.13-fold activation of tk-luc (Figure 2a) . Similarly, in SAOS2 cells, the (p53RE) 5 -tk-luc was activated 216.74-fold by p53 compared to 1.13-fold for tk-luc. This result indicates that the p53-binding element identified in the DN-p63 promoter is sufficient to confer a positive transcriptional response to p53. Cotransfection with DN-p63-a alone into IMECs and SAOS2 cells caused only subtle changes; however, coexpression of p53 and DN-p63-a diminished p53-mediated activation of (p53RE) 5 -tk-luc to 9.29 and 4.52-fold, respectively, indicating that DN-p63-a opposes p53 activity in IMEC and SAOS2 cells (Figure 2a ). This indicates that the p53-binding element in the DN-p63 promoter mediates positive and negative transcriptional regulation in response to over-expression of p53 or DN-p63-a, respectively.
Mutation of the p53/p63 binding element in the DNspecific p63 promoter reduces p53-mediated activation
To determine if the p53-binding element mediates transcriptional responses to p53 and DN-p63-a in the context of the DN-p63 promoter, we mutated the element (see Figure 1c) . Transfection of wild-type (pGL3-26) and mutant (pGL3-26 M) promoters revealed that mutation of this element reduced but did not abolish p53-mediated transcriptional activation (Figure 2b ), suggesting the possibility of additional elements capable of mediating p53 signaling. Consistent with the heterologous promoter studies, DN-p63-a diminished p53-mediated transcriptional activity indicating that in the context of its own promoter, overexpressed DN-p63-a opposes the activity of p53. This indicates that the p53-binding element contributes to positive and negative regulation of DN-p63 promoter activity. Interestingly, we observed a small but consistent enhancement of transcriptional activation in response to DN-p63-a that was independent of the ABCD assays were performed (see Methods) as described, and retained fractions were subjected to Western blotting for detection of p53 and p63. Importantly, neither p53 nor p63 is capable of binding to p53RE-mut p53-binding element (see Discussion). To confirm that DN-p63-a functions as transcriptional repressor in IMECs, the cDNAs for p53 and DN-p63-a were fused to the Gal4 DNA-binding domain, and these fusions were tested for their ability to regulate a Gal4 reporter construct. These studies confirmed that in IMECs, p53 functions as a potent transcriptional activator and DNp63-a as a repressor (Figure 2c) , and support the observation that p53 activates the DN-p63 promoter and that DN-p63-a diminishes this activation.
DN-p63 is a transcriptional target of p53
The identification of a p53 binding that mediates bidirectional regulation of the DN-p63 promoter in response to p53 and DN-p63-a suggested that the DNp63 promoter is a target of p53. We sought to disrupt p53 activity in MCF10A, an immortalized mammary epithelial line previously shown to express DN-p63-a (DiRenzo et al., 2002) through stable expression of the oligomerization domain of p53 (dn-p53) (Shaulian et al., 1992) . This dominant-negative p53 fragment abolished expression of DN-p63-a at both the mRNA and protein levels ( Figure 3a) . We also observed reduced expression of two other p53 targets; p21 and PERP. These studies indicate that p53 activity in MCF10A is necessary for full expression of DN-p63-a and other known p53 targets and support the assertion that DN-p63 is a transcriptional target of p53. Additional dn-p53 caused a reduction in p53 mRNA levels (see Discussion). To confirm that DN-p63 is a transcriptional target of p53, a plasmid capable of directing a p53-specific small inhibitory RNA (Brummelkamp et al., 2002) was stably transfected into IMECs. Importantly, the region of p53 targeted by siRNA has no significant homology with any p63 isoforms. This resulted in a significant decrease in mRNA and protein levels of p53 (Figure 3b ). Northern and Western blot analyses indicated a Figure 2 The p53-binding element identified in the DN-p63 promoter is sufficient to confer transcriptional regulation by p53. (a). The reporter plasmids tk-luc and (p53RE) 5 -tk-luc were transfected into IMEC and SAOS2 cells at 50 ng per well along with 100 ng of pcDNA 3.1 (empty vector control), pRC-CMV-p53, pcDNA 3.1-DN-p63-a, or the combination of pRC-CMV-p53 and pcDNA 3.1-DN-p63-a. Transfections were conducted as described (see Methods). Note the discontinuous Y-axis. Error bars represent the standard deviation of duplicate points from a single representative experiment. (b) Mutation of the p53-binding element located within the DN-p63 promoter reduces but does not abolish p53-mediated induction. Plasmids pGL3-26 and pGL3-26 M contain the entire 10.3 kb fragment identified in Figure 1b and are distinguished only by site-directed mutagenesis of the p53-binding element in pGL3-36 M. These plasmids were transfected at 100 ng per well along with 100 ng of pcDNA 3.1 (empty vector control), pRC-CMV-p53, pcDNA 3.1-DN-p63-a, or the combination of pRC-CMV-p53 and pcDNA 3.1-DN-p63-a. Error bars represent the standard deviation of duplicate points from a single representative experiment. (c) Gal4-fusions studies demonstrate that p53 possesses intrinsic transcriptional activation and DN-p63-a possesses intrinsic transcriptional repression in IMECs. Transfections were carried out with 50 ng of (Gal4) 5 -luc and either 0, 10 or 50 ng of the indicated fusion plasmids. Error bars represent the standard deviation of duplicate points from a single representative experiment. Error bars represent the standard deviation of duplicate points from a single representative experiment. Western blotting confirmed the overexpression of p53 and DN-p63-a (not shown) significant reduction of DN-p63-a mRNA and protein levels demonstrating that expression of p53 is required for full expression of DN-p63-a. Consistent with the dnp53 studies, we also observed a decrease in the expression of p21 and PERP as well as Noxa. Taken together, the dn-p53 and the p53 siRNA studies support the assertion that DN-p63 is a transcriptional target of p53.
Genotoxic stress causes the recruitment of DN-p63-a to the p53-binding element within the DN-p63 promoter and the loss of p63 expression Previous studies in primary keratinocyte cultures have shown a dramatic decline in DN-p63-a mRNA and protein levels in response to ultraviolet B (UV-B) irradiation (Liefer et al., 2000) . This finding is consistent with the prediction that loss of DN-p63-a in response to genotoxic stress would be permissive for p53-mediated apoptosis. We therefore sought to determine if exposure of IMECs to UV-B and other forms of genotoxic stress would lead to changes in the levels of DN-p63-a expression in IMECs. Northern blot analysis (Figure 4a, upper panel) shows that either UV-B or cisplatin diminishes DN-p63-a mRNA as p21 mRNA levels increase. By contrast, doxorubicin failed to diminish DN-p63-a levels and elicited a significant induction of p21 (Figure 4a , middle panel) (see Discussion). Similar treatments of MCF-7, which lack p63 isoforms, resulted in a slight induction of DN-p63-a mRNA in response to UV-B and a more robust induction of p21 in response to UV-B, cisplatin and doxorubicin. The induction of p21 in response to UV-B, cisplatin and doxorubicin in MCF-7 also controls for the efficacy of treatments used in this study. These results indicated that in IMECs, expression of DN-p63-a declines in response to certain types of genotoxic stress. This observation coupled to the identification of a p53-binding element in the DN-p63 promoter suggested that one possible mechanism by which DN-p63-a mRNA levels decline in response to genotoxic stress would be through negative autoregulation. Chromatin immune precipitation (ChIP) assays were conducted to determine if p53 or DN-p63-a could occupy the p53-binding element before and after UV-B irradiation. In nonirradiated IMECs, p53 binding could be detected at the p53-binding element (Figure 5b , upper right panel) providing further evidence that the DN-p63 promoter is a direct target of p53. Under these conditions, a weak signal indicating the presence of DN-p63 at this element was also observed. Following irradiation, we observed Figure 3 Disruption of p53 activity or expression abolishes DNp63 expression. (a) Stable overexpression of the p53 oligomerization domain in MCF10A disrupts p53-mediated transactivation of DN-p63 and other target genes. MCF10A cells were transfected with pcDNA-3.1-D53-2 and stable lines were selected in 400 mg/ml of G418. Antibiotic-resistant clones were analyzed for the expression of p53 and p63 by Northern and Western blot respectively. The expression of p21 and PERP was evaluated by Northern blotting. Note the absence of DN-p63 mRNA or protein in the MCF10A-D53-2 line. (b) Ablation of p53 expression by stable expression of a p53-directed siRNA disrupts expression of DN-p63 and other target genes in IMECs. IMECs were stably transfected with empty pcDNA3.1 (for G418 resistance) and either pSuper (empty) or pSuper-p53. Pooled populations and clonal isolates were derived following selection in 50 mg/ml of G418. The expression of p53 and p63 was evaluated at the RNA and protein level by Northern and Western blotting. The expression of p21, PERP and NOXA was evaluated by Northern blotting and shown to decline in the IMEC-pSuper-p53 relative to IMEC-pSuper. Note the reduction of DN-p63 mRNA and the absence of detectable DNp63-a protein that DN-p63-a, but not p53, occupied the p53-binding element (Figure 5b, lower right panel) . Importantly, the binding of p53 and p63 was detected specifically in the region that contained the p53-binding element and not in a region that is 6 kb upstream of that element (Figure 5b , left panels). These results suggest that one possible mechanism by which the DN-p63 promoter activity is repressed is through the DNA-damagedependent recruitment of DN-p63-a.
Targeted disruption of DN-p63 expression differentially regulates p53 target genes
The finding that the DN-p63 promoter is positively regulated by p53, identifies an autoregulatory loop in which p53 drives the expression of a factor capable of modulating its own transcriptional activity. We therefore sought to determine the role of DN-p63-a in the regulation of p53 target genes in IMECs by disrupting DN-p63-a expression with a p63-specific siRNA. Stable transfectants bearing pSuper-p63 were selected and screened for mRNA and protein expression (Figure 5a) . Several lines were shown to have dramatically reduced DN-p63-a mRNA and of those two had no detectable DN-p63-a protein (Figure 5b ). Analysis of these lines indicated that loss of DN-p63-a leads to an increase in p53 mRNA levels (see Discussion) and a pattern of differential expression of p53 target genes. Loss of DN-p63-a expression leads to increased expression of Figure 4 Negative regulation of DN-p63-a expression in response to genotoxic stress correlates with the recruitment of DN-p63-a to the p53-binding element within the DN-specific p63 promoter, (a) IMECs and MCF-7 cells were grown to 70% confluence and were left untreated or treated in the following manner: UV-B: Cell culture media were aspirated and monolayers were bathed in 3 ml PBS per 10 cm dish. Cells were exposed to 690 mJ of UV-B. Following removal of PBS, cells were refed and RNA was harvested at 20 h. Cisplatin: Cells were treated with 20 mg/ml cisplatin for 2 h. Following treatment, cells were washed in PBS, refed and allowed to recover for 18 additional hours. Doxorubicin: Cells were treated with 1 mM doxorubicin for 20 h. In all cases, RNA was recovered, and Northern blotting was conducted as described in Methods. (b) ChIP assay identifies p53 bound to the p53-binding element of the DN-p63 promoter in asynchronously growing IMECs and recruitment of DN-p63-a in response to UV-B irradiation. Cells were left untreated or irradiated with UV-B as described above. Untreated and irradiated cells were refed and allowed to recover for 18 h. ChIP assays were conducted as described in Methods Figure 5 Disruption of DN-p63 expression in IMECs leads to differential regulation of p53 target genes. (a) Schematic of the hairpin structure predicted to be generated by the plasmid pSuperp63. Shaded regions indicate the p63-targeted sequence and the corresponding amino acids. IMECs were stably transfected with pcDNA-3.1 and pSuper-p63. Pooled populations and clonal isolates were isolated after 16 days of G418 selection at 50 mg/ml. Clonal isolates were shown to have reduced DN-p63 mRNA and none in certain cases and no detectable DN-p63 protein. Ablation of DN-p63 caused an increase in p53 mRNA levels. The expression of p53 target genes revealed an increase in p21and a decrease in PERP and NOXA p21 and decreased expression of PERP and Noxa. These studies indicate that DN-p63-a may make positive and negative contributions to expression of p53 target genes and may be consistent with studies showing that p63 and p73 are required for induction of certain classes of p53 target genes but not others (Costanzo et al., 2002; Flores et al., 2002) .
Discussion
Abundant genetic evidence indicates that p63 functions to maintain regenerative capacity of basal epithelia at several sites throughout the body Irwin and Kaelin, 2001; van Bokhoven and McKeon, 2002; Yang et al., 2002) . We present data that the DN-p63 promoter is a direct target of p53. We report the identification of a p53-binding element within the DN-p63 promoter that is capable of binding p53 and DN-p63-a in vitro and sufficient to confer transcriptional activation in response to p53 over-expression to a heterologous promoter and to the DN-p63 promoter. We present data that p53 occupies this element in asynchronously growing IMECs and that disruption of p53 activity or expression ablates DN-p63 expression in MCF10A and IMECs. These data prove that the DNp63 promoter is a direct transcriptional target of p53 and raise important questions regarding the ability of p53 to regulate DN-p63 expression in a basal epitheliaspecific manner. The fact that p53 is expressed throughout mammary epithelia coupled to the basalcell-restricted expression of DN-p63 isoforms may suggest cell-type-specific differences in the transactivation status of p53 or basal cell-specific coactivation. An alternative model is that DN-p63 promoter activity is silenced during differentiation in a manner that is dominant to p53. Future studies are necessary to determine the mechanisms by which DN-p63 is silenced during cellular differentiation.
We present data that, in response to certain types of genotoxic stress, DN-p63-a is recruited to the p53-binding element and may play an important role in negative autoregulation. Our ChIP data demonstrate enhanced occupancy of the p53-binding element by DN-p63-a in response to genotoxic stress. These studies failed to detect p53 under these conditions, suggesting that p53 binding is disrupted in response to DNA damage or that epitopes of p53 targeted in the ChIP assay are masked by recruitment of DN-p63-a. The absence of p53 following genotoxic stress, at a time when DN-p63 promoter activity is declining, is consistent with the dominant-negative p53 and p53-directed siRNA studies. This suggests that the p53-binding element identified in these studies functions as a bidirectional regulator of DN-p63 promoter activity. Further studies will be necessary to determine if the recruitment of DN-p63-a in response to genotoxic stress is the direct cause of the repression of DN-p63 expression.
Finally, we present data that disruption of DN-p63-a expression had differential effects on the expression of p53 target genes. We find that ablation of DN-p63-a expression resulted in negative regulation of PERP, and Noxa and positive regulation of p21 and p53. The positive regulation of p21 raises interesting questions regarding the cell cycle regulation of IMECs and p63-depleted IMECs. The establishment of these p63-depleted lines in the presence of increased levels of p21 mRNA suggests that the cyclin-dependent kinase inhibitory activity of p21 may be insufficient to cause growth arrest in IMECs. Additional studies will be necessary to elucidate the mechanism(s) by which IMECs progress through the cell cycle in the presence of increased p21. It is interesting to note that two proapoptotic targets of p53, PERP and Noxa appear to be positively regulated by DN-p63 in IMECs. These findings may be consistent with studies demonstrating a role for p63 and p73 in positive regulation of proapoptotic p53-target genes (Costanzo et al., 2002; Flores et al., 2002) further suggesting that our findings may provide a mechanistic explanation for the delayed mammary gland involution observed in p53 null mice. Future studies will be important to evaluate a larger set of p53 target genes to determine which of the functions of p53 are enhanced by DN-p63 and which are repressed.
In this paper, we report the unusual finding that overexpression of DN-p63-a enhances activity of the DN-p63 promoter in a manner that is independent of the p53-binding element. Our data indicate that this activation is strictly dependent upon the context of the DN-p63 promoter. Efforts to identify regions of the DN-p63 promoter that mediate this regulation have implicated several regions of the DN-p63 promoter including the basal promoter. We believe the mechanism underlying this observation is likely to be indirect. Recent studies have identified a mechanism through which expression of DN-p63-a causes the intranuclear accumulation of bcatenin (Patturajan et al., 2002) . This raises the possibility that this indirect mechanism may account for the activation of the DN-p63 promoter by DN-p63-a. Several other studies have suggested that the Wnt pathway may be important for the maintenance of epithelial precursors (Korinek et al., 1998; Barker et al., 1999; Roose et al., 1999) . It will be of particular interest to determine if this mechanism contributes to promoterspecific enhancement observed in Figure 2b .
Our findings suggest a downstream-regulatory loop in which induction of DN-p63 by p53 may modulate selected activities of p53 in basal epithelia. Similar autoregulatory systems have been described for the transcriptional regulation of p73 (Nakagawa et al., 2002) . In this study, we also noted that p53 mRNA levels were diminished by disruption of p53 activity. We believe that these observations are consistent with studies that report declining levels of p53 during cellular differentiation (Westfall et al., 2003) . In this model disruption of p53 activity, via overexpression of dn-p53, leads to loss of DN-p63 and initiation of cellular differentiation. We also observed enhanced p53 mRNA levels following suppression of DN-p63-a. This is consistent with the reduction of p53 mRNA in the presence of dn-p53 and suggests that the p53-positive autoregulatory loop may be disrupted by DN-p63. These findings imply that cellular differentiation depends upon reduction of both p53 and DN-p63, and that loss of DN-p63 without disruption of p53 activity may be insufficient to initiate cellular differentiation. Further evaluation of this feedback system and its role in the initiation of cellular differentiation will be necessary to describe accurately the conditions under which cellular differentiation initiates.
Our finding that DN-p63 is a direct target of p53 raises important questions regarding the significant phenotypic differences between p53 null mice and p63 null mice. Studies have shown that in the oralesophageal epithelia that p63 is overexpressed in p53 null mice (Suliman et al., 2001 ). These differences may be accounted for by distinct patterns of expression or by the fact that the multiple isoforms of p63 found in different cell types may generate a multiplicity of transcriptional outcomes for p53 and p63 target genes in different cell types and in response to different developmental signals. Additionally, there have been reports of p63 target genes that may be distinct from p53 target genes (Sasaki et al., 2002) . Consistent with other reports (Dohn et al., 2001 ), we present data that expression status of DN-p63 affects regulation of p53 target genes, and this finding may also underlie the phenotypic differences between p53 null and p63 null mice. In conjunction with findings presented here, this suggests that expression of p63 may be influenced by additional transcription factors, or that the findings in the p53 null mice suggest compensation by other factors. Given the important role of transcriptional repression of DN-p63 isoforms in the initiation of differentiation of mammary epithelia, it will be of interest to determine if the p53/p63-response element plays a role in mediating cellular signals that initiate differentiation of mammary epithelia. We propose a model in which p53 directs expression of DN-p63 in basal epithelia of the mammary gland resulting in the preservation of basal epithelia during involution and further suggest that p53 plays an active role in the preservation of self-renewal of mammary epithelial progenitors.
Methods
Promoter identification
The DN-p63 promoter was amplified by nested PCR, and yielded products of B0.4, B1.0 and B0.9 kb, respectively. These fragments were cloned by Gateway recombination using p201DONR and BP Clonase in accordance with the manufacturer's instructions. The resulting clones (16.1, DraI; 17.1, EcoRV; 18.1, SspI) were confirmed by DNA sequencing.
Southern blotting
IMEC genomic DNA (20 mg) was digested with the indicated restriction enzymes and resolved in 0.6% agarose. Southern blotting was performed as previously described and the resulting filter was probed with a PCR product representing promoter fragment 17.1.
Northern blotting
RNA was prepared using the acidified phenol method and 5-10 mg was resolved in a 1% agarose denaturing gel, transferred to nylon and hybridized in Rapid-Hyb buffer (AP Biotech). Filters were probed with restriction fragments derived from DN-p63-a, human p53 cDNA, IMAGE clone 4100827 (p21), IMAGE clone 4778854 (PERP) and IMAGE clone 5212537 (Noxa). Hybridizations at 641C for 2 h was followed by washing, such that the final wash was in 0.1 Â SSC/0.5% SDS for 10 min at 651C.
Plasmids
A 10 351 bp fragment of human genomic DNA identified by Southern blotting was identified in the BAC# RP11-37316 (InVitrogen). This fragment was subcloned into pAlter-1 (Promega) and pGL3-basic (Promega). Deletion mutations were made using standard recombinant DNA procedure, and oligo-directed mutagenesis of the p53-binding element was carried out using Altered Sites (Promega) mutagenesis system. The pcDNA-DN-p63-a was made by first amplifying DN-p63-a from the cDNA of IMECs and subcloning into pcDNA 3.1. For the (p53RE) 5 -tk-luc, synthetic multimers were cloned upstream of the HSV thymidine kinase minimal promoter fused to luciferase. The Gal-4-DN-p63-a was synthesized by ligating the cDNA of DN-p63-a into the Gal4-fusion expression plasmid, pM (Clontech). The dominant-negative p53 construction, pcDNA-D53-2, was made by amplifying the regions of p53 that encode the oligomerization domain and ligating into pcDNA3.1. Small inhibitory RNA encoding plasmids with identity to p63 were synthesized based upon predictions generated from the web-based platform of Oligoengine, and cloned into pSuper. The pSuper-p53 siRNA was obtained through Oligoengine.
Cell lines and transient transfections
IMECs are maintained in mammary epithelial growth medium (MEGM) (Clonetics), plated at 250 000 per well in six-well cluster dishes and transfected using Polyfect (Qiagen Cat# 301107). Each well received 100 fmol of reporter plasmid, 50-100 ng of p53 and DN-p63-a expression plasmids, 100 ng of pEGFP for control of transfection efficiency and viability of transfected cells, and 100 ng of a bActin-LacZ. Luciferase assays were performed using the luciferase assay system from Promega according to the manufacturer's protocol. Galactosidase assays were performed using the ONPG method and luciferase data were normalized to galactosidase data to correct for nonspecific regulation. Data are expressed as the fold induction following normalization and error bars represent the standard deviation. SAOS-2 cells were cultured in McCoys 5A medium supplemented with 15% fetal calf serum and transfected by a protocol similar to that of the IMECs. Transfection data are presented either as normalized luciferase activity or as the fold induction of normalized luciferase activity over empty expression vector control (Figure 2 ). All data represent a minimum of three experiments and error bars represent the standard deviations of data generated within a single representative experiment.
Generation and screening of MCF10A and IMEC stable cell lines Cells (1.5 Â 10 6 ) were plated in 10 cm dishes and tranfected with 1 mg of pcDNA3.l and 7 mg of either pEGFP (Clontech), pSuper (Oligoengine), pSuper-p53 (Oligoengine) or pSuperp63. At 24 h post-transfection, each transfectant was split 1 : 7.
At 48 h, selection began with 50 mg/ml of G418. After 16 days of selection, one plate of each transfectant was harvested to establish pooled populations of the stable transfectants. An additional set was used for the establishment of clonal isolates. MCF10A cells were stably transformed with pcDNA3.1-D53-2 and selected in 400 mg/ml of G418.
Nuclear extract preparation
Nuclear extracts were prepared by lysing cells in 1 ml of 1X lysis buffer (25 mM Tris-HCl pH ¼ 7.8, 1 mM DTT, 1 mM EDTA, 5% (v/v) glycerol and 1% Triton X-100) supplemented with protease inhibitors and phosphatase inhibitors. Intact nuclei were collected by gentle centrifugation (3000 r.p.m. at 41C). Nuclei were resuspended in hypotonic buffer (10 mM HEPES pH ¼ 7.9, 10 mM NaCl, 1 mM EDTA, 1 mM DTT and 5% (v/v) glycerol) and the volume was determined. Hypertonic buffer (10 mM HEPES pH ¼ 7.9, 1 M NaCl, 1 mM EDTA, 1 mM DTT and 5% (v/v) glycerol) supplemented with protease and phosphatase inhibitors was added to a final NaCl concentration of 0.42 M. Suspensions were mixed by inversion at 41C for 30 min and cleared by centrifugation (14 000 r.p.m. at 41C).
Avidin biotin-conjugated DNA (ABCD) binding assay
Biotinylated oligonucleotides representing wild-type and mutant elements (see Figure 1c) were annealed and mixed with 20 mg of nuclear extract on ice for 30 min. Protein/DNA complexes were captured using streptavidin-linked agarose washed three times in ice-cold NET-N (20 mM Tris pH ¼ 7.8, 1 mM EDTA, 0.1 M NaCl and 0.5% (v/v) NP-40), eluted by boiling in 2X SDS sample dye and subjected to Western blot analysis.
Chromatin immune precipitation
Confluent 15 cm plates were fixed in 1% formaldehyde and crosslinking was stopped by the addition of glycine to 0.125 M.
Fixed cells were rinsed (2 Â ) with ice-cold PBS, harvested by scraping, collected by centrifugation and resuspended in 300 ml of lysis buffer (1% SDS, 5 mM EDTA, 50 mM Tris-HCl (pH 8.1), 1X protease inhibitor cocktail). Following a 10-min incubation on ice, the lysate was sonicated and the insoluble material was removed by centrifugation. Soluble chromatin was diluted 1 : 10 in chromatin dilution buffer (1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl (pH 8.1) and 1X protease inhibitor cocktail and precleared by incubation with protein-A sepharose beads at 41C. The supernatants were immunocleared with fresh beads and 2 mg/ml of nonspecific murine IgG for 1 h at 41C. Recovered supernatants were incubated overnight with 2 mg of specific antibody and antibody-chromatin complexes were captured with preblocked protein-A magnetic beads. Retained fractions were sequentially washed, and chromatin-antibody complexes were eluted from the beads by detergent extraction. Crosslinking was reversed by overnight incubation at 651C, and recovered DNA was purified and amplified for 25-30 cycles by standard PCR. PCR primer sequences were as follows: 
AACAAAATTAA GTTCCTCCTATTGC
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